UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.24 Million Position in Liquidia Co. (NASDAQ:LQDA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Liquidia Co. (NASDAQ:LQDA - Free Report) by 26.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 105,734 shares of the company's stock after acquiring an additional 22,445 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.12% of Liquidia worth $1,243,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC acquired a new position in Liquidia during the 4th quarter worth about $59,000. Summit Investment Advisors Inc. grew its stake in shares of Liquidia by 35.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock valued at $78,000 after purchasing an additional 1,719 shares during the last quarter. D. E. Shaw & Co. Inc. bought a new stake in shares of Liquidia during the fourth quarter valued at approximately $142,000. EntryPoint Capital LLC acquired a new stake in shares of Liquidia in the fourth quarter valued at approximately $154,000. Finally, Bayesian Capital Management LP bought a new position in Liquidia in the 4th quarter worth approximately $163,000. 64.54% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Liquidia news, insider Jason Adair sold 1,856 shares of the company's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $25,185.92. Following the sale, the insider now directly owns 184,304 shares of the company's stock, valued at approximately $2,501,005.28. This represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Rajeev Saggar sold 2,450 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of $13.67, for a total transaction of $33,491.50. Following the completion of the sale, the insider now owns 263,152 shares of the company's stock, valued at approximately $3,597,287.84. This represents a 0.92% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,138 shares of company stock valued at $450,233 in the last quarter. 26.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on LQDA. Scotiabank lifted their target price on Liquidia from $36.00 to $37.00 and gave the company a "sector outperform" rating in a research note on Wednesday, May 28th. Wells Fargo & Company boosted their price objective on Liquidia from $20.00 to $23.00 and gave the stock an "overweight" rating in a report on Wednesday, May 28th. Oppenheimer set a $13.00 target price on shares of Liquidia and gave the company an "underperform" rating in a research note on Monday, May 19th. HC Wainwright boosted their price target on shares of Liquidia from $29.00 to $35.00 and gave the stock a "buy" rating in a research note on Wednesday, May 28th. Finally, Needham & Company LLC reaffirmed a "buy" rating on shares of Liquidia in a report on Monday, June 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Liquidia presently has a consensus rating of "Moderate Buy" and a consensus target price of $26.67.

Liquidia Stock Down 5.7%

LQDA traded down $0.85 during trading on Wednesday, hitting $14.13. The company had a trading volume of 5,299,441 shares, compared to its average volume of 1,191,604. The company has a market capitalization of $1.21 billion, a PE ratio of -8.67 and a beta of 0.04. Liquidia Co. has a one year low of $8.26 and a one year high of $19.41. The firm's 50-day moving average price is $15.08 and its 200 day moving average price is $14.09.

Liquidia (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The firm had revenue of $3.12 million during the quarter, compared to analyst estimates of $3.23 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. Sell-side analysts forecast that Liquidia Co. will post -1.51 earnings per share for the current year.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).